Adial Pharmaceuticals, Inc. (ADIL)
| Market Cap | 10.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.70M |
| Shares Out | 28.52M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,766 |
| Open | 0.358 |
| Previous Close | 0.358 |
| Day's Range | 0.340 - 0.359 |
| 52-Week Range | 0.200 - 2.270 |
| Beta | 0.98 |
| Analysts | Buy |
| Price Target | 7.65 (+2,150.0%) |
| Earnings Date | May 15, 2023 |
About ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ADIL stock is "Buy." The 12-month stock price forecast is $7.65, which is an increase of 2,150.00% from the latest price.
News
Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update
Secured meetings with U.S. and European regulatory agencies
Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder
The Keswick Group is led by experienced pharmaceutical business development executive, Tony Goodman The Keswick Group is led by experienced pharmaceutical business development executive, Tony Goodman
Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th
CHARLOTTESVILLE, Va., March 08, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ...
Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder
Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023; plans in place to meet with multiple European regulatory authorities
Adial Pharmaceuticals Schedules Business Update Conference Call
CHARLOTTESVILLE, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ...
Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering
CHARLOTTESVILLE, Va., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing t...
Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering
CHARLOTTESVILLE, Va., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing t...
Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed
Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley
Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisi...
Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds
Forget Bargain Hunting: Play 5 Stocks With Rising P/E
Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enter...
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate's PNV-5030 as a Potential Treatment for Chronic Pain
PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 significantly reduced pain compared to both placebo and acetaminophen
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate's PNV-6005 as a Potential Treatment for Ulcerative Colitis
PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model
Here's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom Fisher
Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisi...
Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer
Kevin Schuyler appointed Chairman of Adial's Board
Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
Reported positive topline results for ONWARD™ Phase 3 trial of AD04 for the treatment of Alcohol Use Disorder
What's Going On With Adial Pharmaceuticals Stock Today?
Shares of small-cap penny stock Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) shares are trading about 20.5% lower at $1.46 per share Wednesday morning. The company announced topline results for its Onwa...
Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinki...
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET
Twin Vee PowerCats Co.'s Board of Directors Appoints Kevin Schuyler as Newest Director
FORT PIERCE, FL / ACCESSWIRE / July 7, 2022 / Twin Vee PowerCats Co. (Nasdaq:VEEE) ("Twin Vee" or the "Company"), a designer, manufacturer, distributor, and marketer of power sport catamaran boats, to...
Adial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley
CHARLOTTESVILLE, Va., June 28, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today issued the following letter to its shareholders from the Com...
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial
Expects Release of Top-Line Data in July Expects Release of Top-Line Data in July
Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company's Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence
New patent covers the use of the full genetic panel measuring all five genetic biomarkers New patent covers the use of the full genetic panel measuring all five genetic biomarkers
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate's Adenosine Compounds as Potential Treatments for Diabetes and NASH
CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on d...
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter